Efficacy and safety of surufatinib in United States (US) patients (pts) with neuroendocrine tumors (NETs).

4610Background: Surufatinib (S) is a targeted inhibitor of tyrosine kinases VEGFR1, 2, & 3, FGFR1, and CSF-1R. Safety and efficacy of S has previously been studied in China in early phase developme...